Drugs

, Volume 74, Issue 2, pp 223–242

Sitagliptin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus

Adis Drug Evaluation

Abstract

Sitagliptin (Januvia®, Xelevia™, Glactiv®, Tesavel®) is an orally administered, potent and highly selective inhibitor of dipeptidyl peptidase-4 (DPP-4) and was the first agent of its class to be approved for use in the management of adults with type 2 diabetes. Numerous randomized placebo- or active comparator-controlled trials have demonstrated the efficacy of sitagliptin in terms of improving glycaemic control in patients with type 2 diabetes, including its use as monotherapy, initial combination therapy (usually with fixed-dose combinations of sitagliptin/metformin), or add-on therapy to metformin or to other antihyperglycaemic drugs, with or without metformin. The primary endpoint of the clinical trials was the reduction from baseline in glycosylated haemoglobin (HbA1c), although sitagliptin also showed beneficial effects for other endpoints, such as the proportion of patients who achieved target HbA1c, and reductions from baseline in fasting plasma glucose (FPG) levels and 2-h postprandial glucose (PPG) levels. Sitagliptin was generally well tolerated in clinical trials, had a low risk of hypoglycaemia (although this depends on background therapy) and had a neutral effect on body weight. Despite concerns regarding a possible increased risk of rare pancreatic adverse events (e.g. pancreatitis) with glucagon-like peptide-1 (GLP-1)-based therapies, such as GLP-1 receptor agonists and DPP-4 inhibitors, no causal association has been found; regulators in Europe recently conducted a review of available data, concluding that there is little evidence that these drugs could cause pancreatic inflammation or pancreatic cancer. A similar review is planned in the USA and postmarketing surveillance will continue. Thus, oral sitagliptin is an effective and generally well tolerated treatment option for the management of patients with type 2 diabetes.

References

  1. 1.
    Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364–79.PubMedGoogle Scholar
  2. 2.
    American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2012;35 Suppl 1:S64–71.Google Scholar
  3. 3.
    American Diabetes Association. Standards of medical care in diabetes. Diabetes Care. 2012;35 Suppl 1:S11–63.Google Scholar
  4. 4.
    International Diabetes Federation. Global diabetes plan 2011–2021. http://www.idf.org/sites/default/files/Global_Diabetes_Plan_Final.pdf. Accessed 11 Jul 2013.
  5. 5.
    Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87(1):4–14.PubMedGoogle Scholar
  6. 6.
    Roglic G, Unwin N. Mortality attributable to diabetes: estimates for the year 2010. Diabetes Res Clin Pract. 2010;87(1):15–9.PubMedGoogle Scholar
  7. 7.
    Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405–12.PubMedGoogle Scholar
  8. 8.
    Moss SE, Klein R, Klein BE, et al. The association of glycemia and cause-specific mortality in a diabetic population. Arch Intern Med. 1994;154(21):2473–9.PubMedGoogle Scholar
  9. 9.
    Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999;281(21):2005–12.PubMedGoogle Scholar
  10. 10.
    Inzucchi SE, McGuire DK. New drugs for the treatment of diabetes: part II. Incretin-based therapy and beyond. Circulation. 2008;117(4):574–84.PubMedGoogle Scholar
  11. 11.
    Ahren B. Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications. Diabetes Care. 2007;30(6):1344–50.PubMedGoogle Scholar
  12. 12.
    Campbell RK. Rationale for dipeptidyl peptidase 4 inhibitors: a new class of oral agents for the treatment of type 2 diabetes mellitus. Ann Pharmacother. 2007;41(1):51–60.PubMedGoogle Scholar
  13. 13.
    Rosenstock J, Zinman B. Dipeptidyl peptidase-4 inhibitors and the management of type 2 diabetes mellitus. Curr Opin Endocrinol Diabetes Obes. 2007;14(2):98–107.PubMedGoogle Scholar
  14. 14.
    Dhillon S. Sitagliptin: a review of its use in the management of type 2 diabetes mellitus. Drugs. 2010;70(4):489–512.PubMedGoogle Scholar
  15. 15.
    Sitagliptin (Januvia) US prescribing information. 2013. http://www.merck.com/product/usa/pi_circulars/j/januvia/januvia_pi.pdf. Accessed 9 Jul 2013.
  16. 16.
    Sitagliptin summary of product characteristics. 2013. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000722/WC500039054.pdf. Accessed 9 Jul 2013.
  17. 17.
    Kim D, Wang L, Beconi M, et al. (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1, 2, 4]triazolo[4,3-a]pyrazin-7(8H)- yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem. 2005;48(1):141–51.PubMedGoogle Scholar
  18. 18.
    Bergman AJ, Stevens C, Zhou Y, et al. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. Clin Ther. 2006;28(1):55–72.PubMedGoogle Scholar
  19. 19.
    Herman GA, Bergman A, Liu F, et al. Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects. J Clin Pharmacol. 2006;46(8):876–86.PubMedGoogle Scholar
  20. 20.
    Herman GA, Bergman A, Stevens C, et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab. 2006;91(11):4612–9.PubMedGoogle Scholar
  21. 21.
    Herman GA, Stevens C, Van Dyck K, et al. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther. 2005;78(6):675–88.PubMedGoogle Scholar
  22. 22.
    Lyseng-Williamson KA. Sitagliptin. Drugs. 2007;67(4):587–97.PubMedGoogle Scholar
  23. 23.
    Golightly LK, Drayna CC, McDermott MT. Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors. Clin Pharmacokinet. 2012;51(8):501–14.PubMedGoogle Scholar
  24. 24.
    Bergman A, Mistry GC, Luo WL, et al. Dose-proportionality of a final market image sitagliptin formulation, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers. Biopharm Drug Dispos. 2007;28(6):307–13.PubMedGoogle Scholar
  25. 25.
    Bergman A, Ebel D, Liu F, et al. Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers. Biopharm Drug Dispos. 2007;28(6):315–22.PubMedGoogle Scholar
  26. 26.
    Vincent SH, Reed JR, Bergman AJ, et al. Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans. Drug Metab Dispos. 2007;35(4):533–8.PubMedGoogle Scholar
  27. 27.
    Migoya EM, Stevens CH, Bergman AJ, et al. Effect of moderate hepatic insufficiency on the pharmacokinetics of sitagliptin. Can J Clin Pharmacol. 2009;16(1):e165–70.PubMedGoogle Scholar
  28. 28.
    Bergman AJ, Cote J, Yi B, et al. Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor. Diabetes Care. 2007;30(7):1862–4.PubMedGoogle Scholar
  29. 29.
    Fraser I, Neufeld N, Fox LA, et al. Pharmacokinetics and pharmacodynamics of sitagliptin in adolescents with type 2 diabetes [abstract]. 73rd Annual Meeting of the American Diabetes Association; 21–25 June 2013; Chicago (IL).Google Scholar
  30. 30.
    Herman GA, Mistry GC, Yi B, et al. Evaluation of pharmacokinetic parameters and dipeptidyl peptidase-4 inhibition following single doses of sitagliptin in healthy, young Japanese males. Br J Clin Pharmacol. 2011;71(3):429–36.PubMedGoogle Scholar
  31. 31.
    Migoya E, Larson P, Bergman A, et al. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, does not affect the pharmacokinetics of ethinyl estradiol or norethindrone in healthy female subjects. J Clin Pharmacol. 2011;51(9):1319–25.PubMedGoogle Scholar
  32. 32.
    Mistry GC, Bergman AJ, Zheng W, et al. Sitagliptin, an dipeptidyl peptidase-4 inhibitor, does not alter the pharmacokinetics of the sulphonylurea, glyburide, in healthy subjects. Br J Clin Pharmacol. 2008;66(1):36–42.PubMedGoogle Scholar
  33. 33.
    Cerra M, Luo WL, Li S, et al. Effect of simvastatin on the pharmacokinetics of sitagliptin. J Popul Ther Clin Pharmacol. 2012;19(3):e356–60.PubMedGoogle Scholar
  34. 34.
    Migoya EM, Miller JL, Gutierrez M, et al. Bioequivalence of sitagliptin/metformin fixed-dose combination tablets and concomitant administration of sitagliptin and metformin in healthy adult subjects: a randomized, open-label, crossover study. Clin Drug Investig. 2010;30(12):855–66.PubMedGoogle Scholar
  35. 35.
    Iwamoto Y, Taniguchi T, Nonaka K, et al. Dose-ranging efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus. Endocr J. 2010;57(5):383–94.PubMedGoogle Scholar
  36. 36.
    Hanefeld M, Herman GA, Wu M, et al. Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes. Curr Med Res Opin. 2007;23(6):1329–39.PubMedGoogle Scholar
  37. 37.
    Scott R, Wu M, Sanchez M, et al. Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. Int J Clin Pract. 2007;61(1):171–80.PubMedGoogle Scholar
  38. 38.
    Aschner P, Kipnes MS, Lunceford JK, et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 2006;29(12):2632–7.PubMedGoogle Scholar
  39. 39.
    Barzilai N, Guo H, Mahoney EM, et al. Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. Curr Med Res Opin. 2011;27(5):1049–58.PubMedGoogle Scholar
  40. 40.
    Mohan V, Yang W, Son HY, et al. Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea. Diabetes Res Clin Pract. 2009;83(1):106–16.PubMedGoogle Scholar
  41. 41.
    Nonaka K, Kakikawa T, Sato A, et al. Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract. 2008;79(2):291–8.PubMedGoogle Scholar
  42. 42.
    Raz I, Hanefeld M, Xu L, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia. 2006;49(11):2564–71.PubMedGoogle Scholar
  43. 43.
    Aschner P, Katzeff HL, Guo H, et al. Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes. Diabetes Obes Metab. 2010;12(3):252–61.PubMedGoogle Scholar
  44. 44.
    Iwamoto Y, Tajima N, Kadowaki T, et al. Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial. Diabetes Obes Metab. 2010;12(7):613–22.PubMedGoogle Scholar
  45. 45.
    Russell-Jones D, Cuddihy RM, Hanefeld M, et al. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study. Diabetes Care. 2012;35(2):252–8.PubMedGoogle Scholar
  46. 46.
    Arjona Ferreira JC, Marre M, Barzilai N, et al. Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes andmoderate-to-severe chronic renal insufficiency. Diabetes Care. 2013;36(5):1067–73.PubMedGoogle Scholar
  47. 47.
    Arjona Ferreira JC, Corry D, Mogensen CE, et al. Efficacy and safety of sitagliptin in patients with type 2 diabetes and ESRD receiving dialysis: a 54-week randomized trial. Am J Kidney Dis. 2013;61(4):579–87.PubMedGoogle Scholar
  48. 48.
    Arjona Ferreira JC, Engel SS, Guo H, et al. Consistency of the A1C-lowering effects of sitagliptin versus glipizide in patients with type 2 diabetes and chronic renal insufficiency across a variety of baseline characteristics [abstract no. 1089-P]. Diabetes. 2012;61 Suppl 1:A281.Google Scholar
  49. 49.
    Arjona Ferreira JC, Engel SS, Guo H, et al. Sitagliptin more effectively achieves a composite endpoint of a1c reduction, no body weight gain, and lack of hypoglycemia in patients with type 2 diabetes and renal insufficiency compared to glipizide [abstract no. 1009-P). Diabetes. 2012;61 Suppl 1:A258.Google Scholar
  50. 50.
    Chan JC, Scott R, Arjona Ferreira JC, et al. Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes Obes Metab. 2008;10(7):545–55.PubMedGoogle Scholar
  51. 51.
    Engel SS, Xu L, Golm GT, et al. Comparison of treatment with sitagliptin (SITA) or sulfonylurea (SU) in patients with type 2 diabetes mellitus (T2DM) and mild renal insufficiency [abstract]. 73rd Annual Meeting of the American Diabetes Association; 21–25 June 2013; Chicago (IL).Google Scholar
  52. 52.
    Kubota A, Maeda H, Kanamori A, et al. Efficacy and safety of sitagliptin monotherapy and combination therapy in Japanese type 2 diabetes patients. J Diabetes Investig. 2012;3(6):503–9.Google Scholar
  53. 53.
    Arase Y, Suzuki F, Suzuki Y, et al. Efficacy and safety in sitagliptin therapy for diabetes complicated by chronic liver disease caused by hepatitis C virus. Hepatol Res. 2011;41(6):524–9.PubMedGoogle Scholar
  54. 54.
    Odawara M, Kadowaki T, Tajima N, et al. Long-term safety, tolerability, and efficacy of the dipeptidyl peptidase-4 inhibitor sitagliptin in Japanese patients with type 2 diabetes. Diabetol Int. 2011;2(2):94–105.Google Scholar
  55. 55.
    Goldstein BJ, Feinglos MN, Lunceford JK, et al. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care. 2007;30(8):1979–87.PubMedGoogle Scholar
  56. 56.
    Williams-Herman D, Johnson J, Teng R, et al. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Curr Med Res Opin. 2009;25(3):569–83.PubMedGoogle Scholar
  57. 57.
    Williams-Herman D, Johnson J, Teng R, et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes Obes Metab. 2010;12(5):442–51.PubMedGoogle Scholar
  58. 58.
    Reasner C, Olansky L, Seck TL, et al. The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2011;13(7):644–52.PubMedGoogle Scholar
  59. 59.
    Olansky L, Reasner C, Seck TL, et al. A treatment strategy implementing combination therapy with sitagliptin and metformin results in superior glycaemic control versus metformin monotherapy due to a low rate of addition of antihyperglycaemic agents. Diabetes Obes Metab. 2011;13(9):841–9.PubMedGoogle Scholar
  60. 60.
    Wainstein J, Katz L, Engel SS, et al. Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes. Diabetes Obes Metab. 2012;14(5):409–18.PubMedGoogle Scholar
  61. 61.
    Sitagliptin/metformin (Janumet) US prescribing information. 2013. http://www.merck.com/product/usa/pi_circulars/j/janumet/janumet_pi.pdf. Accessed 25 Jul 2013.
  62. 62.
    Sitagliptin and metformin extended-release (Janumet XR) US prescribing information. 2013. http://www.merck.com/product/usa/pi_circulars/j/janumet_xr/janumet_xr_pi.pdf. Accessed 25 Jul 2013.
  63. 63.
    Sitagliptin/metformin (Efficib) summary of product characteristics. 2013. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000896/WC500021374.pdf. Accessed 25 Jul 2013.
  64. 64.
    Chwieduk CM. Sitagliptin/metformin fixed-dose combination: in patients with type 2 diabetes mellitus. Drugs. 2011;71(3):349–61.PubMedGoogle Scholar
  65. 65.
    Yoon KH, Shockey GR, Teng R, et al. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of β-cell function in patients with type 2 diabetes. Int J Clin Pract. 2011;65(2):154–64.PubMedGoogle Scholar
  66. 66.
    Perez-Monteverde A, Seck T, Xu L, et al. Efficacy and safety of sitagliptin and the fixed-dose combination of sitagliptin and metformin vs. pioglitazone in drug-naive patients with type 2 diabetes. Int J Clin Pract. 2011;65(9):930–8.PubMedGoogle Scholar
  67. 67.
    Henry RR, Staels B, Fonseca VA, et al. Efficacy and safety of initial combination treatment with sitagliptin and pioglitazone - a factorial study [abstract no. O-0597]. 21st World Diabetes Congress; 4–8 Dec 2011; Dubai.Google Scholar
  68. 68.
    Charbonnel B, Karasik A, Liu J, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care. 2006;29(12):2638–43.PubMedGoogle Scholar
  69. 69.
    Kadowaki T, Tajima N, Odawara M, et al. Addition of sitagliptin to ongoing metformin monotherapy improves glycemic control in Japanese patients with type 2 diabetes over 52 weeks. J Diabetes Investig. 2013;4(2):174–81.Google Scholar
  70. 70.
    Raz I, Chen Y, Wu M, et al. Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes. Curr Med Res Opin. 2008;24(2):537–50.PubMedGoogle Scholar
  71. 71.
    Yang W, Guan Y, Shentu Y, et al. The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes. J Diabetes. 2012;4(3):227–37.PubMedGoogle Scholar
  72. 72.
    Arechavaleta R, Seck T, Chen Y, et al. Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab. 2011;13(2):160–8.PubMedGoogle Scholar
  73. 73.
    Aschner P, Chan J, Owens DR, et al. Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial. Lancet. 2012;379(9833):2262–9.PubMedGoogle Scholar
  74. 74.
    Bergenstal RM, Wysham C, Macconell L, et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet. 2010;376(9739):431–9.PubMedGoogle Scholar
  75. 75.
    Nauck MA, Meininger G, Sheng D, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab. 2007;9(2):194–205.PubMedGoogle Scholar
  76. 76.
    Pratley RE, Nauck M, Bailey T, et al. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial [Erratum appears in Lancet. 2010 Jul 24;376(9737):234]. Lancet. 2010;375(9724):1447–56.PubMedGoogle Scholar
  77. 77.
    Scheen AJ, Charpentier G, Ostgren CJ, et al. Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus. Diabetes Metab Res Rev. 2010;26(7):540–9.PubMedGoogle Scholar
  78. 78.
    Scott R, Loeys T, Davies MJ, et al. Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes Obes Metab. 2008;10(10):959–69.PubMedGoogle Scholar
  79. 79.
    Seck T, Nauck M, Sheng D, et al. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study. Int J Clin Pract. 2010;64(5):562–76.PubMedGoogle Scholar
  80. 80.
    Best JH, Rubin RR, Peyrot M, et al. Weight-related quality of life, health utility, psychological well-being, and satisfaction with exenatide once weekly compared with sitagliptin or pioglitazone after 26 weeks of treatment. Diabetes Care. 2011;34(2):314–9.PubMedGoogle Scholar
  81. 81.
    Pratley R, Nauck M, Bailey T, et al. One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial. Int J Clin Pract. 2011;65(4):397–407.PubMedCentralPubMedGoogle Scholar
  82. 82.
    Pratley RE, Nauck MA, Bailey T, et al. Efficacy and safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 weeks in metformin-treated patients with type 2 diabetes: a randomized, open-label trial. Diabetes Care. 2012;35(10):1986–93.PubMedGoogle Scholar
  83. 83.
    Dobs AS, Goldstein BJ, Aschner P, et al. Efficacy and safety of sitagliptin added to ongoing metformin and rosiglitazone combination therapy in a randomized placebo-controlled 54-week trial in patients with type 2 diabetes. J Diabetes. 2013;5(1):68–79.PubMedGoogle Scholar
  84. 84.
    Fonseca V, Staels B, Morgan IJD, et al. Efficacy and safety of sitagliptin added to ongoing metformin and pioglitazone combination therapy in a randomized, placebo-controlled, 26-week trial in patients with type 2 diabetes. J Diabetes Complications. 2013;27(2):177–83.PubMedGoogle Scholar
  85. 85.
    Kashiwagi A, Kadowaki T, Tajima N, et al. Sitagliptin added to treatment with ongoing pioglitazone for up to 52 weeks improves glycemic control in Japanese patients with type 2 diabetes. J Diabetes Investig. 2011;2(5):381–90.Google Scholar
  86. 86.
    Rosenstock J, Brazg R, Andryuk PJ, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2006;28(10):1556–68.PubMedGoogle Scholar
  87. 87.
    Hermansen K, Kipnes M, Luo E, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab. 2007;9(5):733–45.PubMedGoogle Scholar
  88. 88.
    Round E, Shentu Y, Golm GT, et al. Safety and efficacy of sitagliptin added to the combination of sulfonylurea and metformin in patients with type 2 diabetes mellitus and inadequate glycemic control [abstract]. 73rd Annual Meeting of the American Diabetes Association; 21–25 June. 2013; Chicago (IL).Google Scholar
  89. 89.
    Tajima N, Kadowaki T, Odawara M, et al. Addition of sitagliptin to ongoing glimepiride therapy in Japanese patients with type 2 diabetes over 52 weeks leads to improved glycemic control. Diabetol Int. 2011;2(1):32–44.Google Scholar
  90. 90.
    Kadowaki T, Tajima N, Odawara M, et al. Addition of sitagliptin, an oral, highly-selective dipeptidyl peptidase-4 inhibitor, improved glycemic control and was well tolerated in Japanese patients with type 2 diabetes on insulin monotherapy. Diabetes. 2011;60:A279–80.Google Scholar
  91. 91.
    Vilsboll T, Rosenstock J, Yki-Jarvinen H, et al. Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. Diabetes Obes Metab. 2010;12(2):167–77.PubMedGoogle Scholar
  92. 92.
    Deacon CF, Holst JJ. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety. Expert Opin Pharmacother. 2013;14(15):2047–58.PubMedGoogle Scholar
  93. 93.
    Engel SS, Round E, Golm GT, et al. Safety and tolerability of sitagliptin in type 2 diabetes: pooled analysis of 25 clinical studies (Erratum appears in Diabetes Ther. 2013;4(2):487). Diabetes Ther. 2013;4(1):119–45.PubMedCentralPubMedGoogle Scholar
  94. 94.
    Eurich DT, Simpson S, Senthilselvan A, et al. Comparative safety and effectiveness of sitagliptin in patients with type 2 diabetes: retrospective population based cohort study. BMJ. 2013;346:f2267.PubMedCentralPubMedGoogle Scholar
  95. 95.
    Engel SS, Williams-Herman DE, Golm GT, et al. Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis. Int J Clin Pract. 2010;64(7):984–90.PubMedCentralPubMedGoogle Scholar
  96. 96.
    Elashoff M, Matveyenko AV, Gier B, et al. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology. 2011;141(1):150–6.PubMedGoogle Scholar
  97. 97.
    Butler AE, Campbell-Thompson M, Gurlo T, et al. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes. 2013;62(7):2595–604.PubMedGoogle Scholar
  98. 98.
    Dore DD, Seeger JD. Arnold Chan K. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin. 2009;25(4):1019–27.PubMedGoogle Scholar
  99. 99.
    Garg R, Chen W, Pendergrass M. Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis. Diabetes Care. 2010;33(11):2349–54.PubMedGoogle Scholar
  100. 100.
    Monami M, Dicembrini I, Martelli D, et al. Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials. Curr Med Res Opin. 2011;27 Suppl 3:57–64.PubMedGoogle Scholar
  101. 101.
    Singh S, Chang H-Y, Richards TM, et al. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern Med. 2013;173(7):534–9.PubMedGoogle Scholar
  102. 102.
    Brodovicz KG, Engel SS, Thornberry NA. Glucagon-like peptide 1-based drugs and pancreatic safety [letter]. JAMA Intern Med. 2013;173(19):1842–3.PubMedGoogle Scholar
  103. 103.
    Scheen A. Gliptins (dipeptidyl peptidase-4 inhibitors) and risk of acute pancreatitis. Expert Opin Drug Saf. 2013;12(4):545–57.PubMedGoogle Scholar
  104. 104.
    Pollack A. European regulator finds little risk in diabetes drugs. 2013. http://www.nytimes.com/2013/07/27/business/european-regulator-finds-little-risk-in-diabetes-drugs.html?_r=1. Accessed 11 Sept 2013.
  105. 105.
    Engel SS, Golm GT, Shapiro D, et al. Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis. Cardiovasc Diabetol. 2013;12(1):3.PubMedCentralPubMedGoogle Scholar
  106. 106.
    Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317–26.PubMedGoogle Scholar
  107. 107.
    White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327–35.PubMedGoogle Scholar
  108. 108.
    Scheen AJ. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes. Postgrad Med. 2013;125(3):7–20.PubMedGoogle Scholar
  109. 109.
    Bloomfield DM, Krishna R, Hreniuk D, et al. A thorough QTc study to assess the effect of sitagliptin, a DPP4 inhibitor, on ventricular repolarization in healthy subjects. J Clin Pharmacol. 2009;49(8):937–46.PubMedGoogle Scholar
  110. 110.
    Pendergrass M, Fenton C, Haffner SM, et al. Exenatide and sitagliptin are not associated with increased risk of acute renal failure: a retrospective claims analysis. Diabetes Obes Metab. 2012;14(7):596–600.PubMedGoogle Scholar
  111. 111.
    Glactiv (sitagliptin phosphate hydrate tablets): Japanese prescribing information. Osaka: Ono Pharmaceutical Co., Ltd. 2013.Google Scholar
  112. 112.
    Plosker GL. Dapagliflozin: a review of its use in type 2 diabetes mellitus. Drugs. 2012;72(17):2289–312.PubMedGoogle Scholar
  113. 113.
    Deeks ED. Linagliptin: a review of its use in the management of type 2 diabetes mellitus. Drugs. 2012;72(13):1793–824.PubMedGoogle Scholar
  114. 114.
    Tahrani AA, Bailey CJ, Del Prato S, et al. Management of type 2 diabetes: new and future developments in treatment. Lancet. 2011;378(9786):182–97.PubMedGoogle Scholar
  115. 115.
    Barnett AH. New treatments in type 2 diabetes: a focus on the incretin-based therapies. Clin Endocrinol (Oxf). 2009;70(3):343–53.PubMedGoogle Scholar
  116. 116.
    Burgmaier M, Heinrich C, Marx N. Cardiovascular effects of GLP-1 and GLP-1-based therapies: implications for the cardiovascular continuum in diabetes? Diabet Med. 2013;30(3):289–99.PubMedGoogle Scholar
  117. 117.
    Peters AL. Patient and treatment perspectives: revisiting the link between type 2 diabetes, weight gain, and cardiovascular risk. Cleve Clin J Med. 2009;76 Suppl 5:S20–7.PubMedGoogle Scholar
  118. 118.
    Schwarz B, Gouveia M, Chen J, et al. Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy. Diabetes Obes Metab. 2008;10 Suppl 1:43–55.PubMedGoogle Scholar
  119. 119.
    Lage MJ, Fabunmi R, Boye KS. Comparison of costs among patients with type 2 diabetes treated with exenatide or sitagliptin therapy. Adv Ther. 2009;26:217–29.PubMedGoogle Scholar
  120. 120.
    Langer J, Hunt B, Valentine WJ. Evaluating the short-term cost-effectiveness of liraglutide versus sitagliptin in patients with type 2 diabetes failing metformin monotherapy in the United States. J Manag Care Pharm. 2013;19:237–46.PubMedGoogle Scholar
  121. 121.
    Kaltenboeck A, Ivanova J, Thomas N, et al. Health care resource use and costs in patients with type 2 diabetes mellitus after treatment initiation with saxagliptin or sitagliptin [abstract no. PDB31]. Value Health. 2013;16(3):A161.Google Scholar
  122. 122.
    Hutchings A, Tolley K, Achana F, et al. Cost-effectiveness of saxagliptin compared to sitagliptin for the treatment of patients with type 2 diabetes mellitus (T2DM) [abstract no. PDB39]. Value Health. 2011;14(7):A478.Google Scholar
  123. 123.
    Romero M, Marrugo R, Sanchez O, et al. Cost-effectiveness analysis of using hypoglycemic agents (linagliptin, saxagliptin, sitagliptin, vildagliptin, glimepiride and glibenclamide) with metformin in diabetes in Colombia [abstract no. PDB44]. Value Health. 2013;16(3):A163.Google Scholar
  124. 124.
    Wilson BP, Beaudet A, Caputo J, et al. Projected long-term clinical and economic outcomes of exenatide once weekly versus sitagliptin for the treatment of Type 2 diabetes in the UK [abstract no. P371]. Diabet Med. 2012;29 Suppl 1:142.Google Scholar
  125. 125.
    Schlander M, Mentrup S, Lund N. Addition of incretin-therapy to metformin in type-2-diabetes mellitus (T2DM): cost-effectiveness of liraglutide versus sitagliptin from the perspective of the German statutory health insurance (SHI) [abstract no. PDB38]. Value Health. 2010;13(7):A290.Google Scholar
  126. 126.
    Aledort Gaebler J, Samyshkin Y, Guillermin ALG, et al. Long-term cost-consequence analysis of exenatide once weekly versus sitagliptin or pioglitazone in type 2 diabetes patients in the United States [abstract no. PDB36]. Value Health. 2010;13 (7):A290.Google Scholar
  127. 127.
    Lee WC, Samyshkin Y, Langer J, et al. Long-term clinical and economic outcomes associated with liraglutide versus sitagliptin therapy when added to metformin in the treatment of type 2 diabetes: a CORE Diabetes Model analysis. J Med Econ. 2012;15 Suppl 2:28–37.PubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2014

Authors and Affiliations

  1. 1.AdisNorth ShoreNew Zealand

Personalised recommendations